How the FDA is using real-world evidence in safety and approval decisions
Regulatory decision-making depends on evidence that reflects how medical products perform in...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL). While PPRL remains essential for de-identified data exchange, the study presented during our recent webinar shows that certain token-based approaches...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Early signals indicate continued declines in influenza vaccination uptake and shifts in the...
Our team had a great time at HCIC connecting with healthcare marketers, digital teams and consumer...
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Veterans Day invites us to look beyond branch and rank to the people and stories behind the...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
Regulatory decision-making depends on evidence that reflects how medical products perform in real-world use, not only in controlled trials. For more than a decade, the Food and Drug Administration has relied on real-world data and real-world evidence...